Evaluation and management of difficult-to-control asthma Source: Annual Congress 2007 - PG1 - Asthma: from bench to bedside Year: 2007
COPD patients with asthma, characteristics and risk of exacerbations Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019
Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma Source: Eur Respir J, 58 (6) 2100413; 10.1183/13993003.00413-2021 Year: 2021
Risk factors for severe exacerbations in a real-life population of adults with severe refractory asthma Source: International Congress 2017 – Many faces of asthma and allergies Year: 2017
Risk factors for severe exacerbations in asthma Source: Eur Respir J 2002; 20: Suppl. 38, 199s Year: 2002
Frequency and clinical characteristics of rapid-onset fatal and near-fatal asthma Source: Eur Respir J 2002; 19: 846-852 Year: 2002
Management of difficult-to-treat severe asthma Source: Eur Respir Mon 2011; 51: 282-296 Year: 2011
Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017
Perennial allergy is a modifiable risk factor for exacerbations and respiratory infections in asthma patients Source: Virtual Congress 2020 – Determinants of chronic respiratory diseases Year: 2020
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005
Predicting persistent disease among children who wheeze during early life Source: Eur Respir J 2003; 22: 767-771 Year: 2003
Dupilumab reduces severe exacerbations in periostin-high and periostin-low asthma patients Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives Year: 2016
Exacerbations in severe persistent asthma - impact of risk factors control Source: Eur Respir J 2005; 26: Suppl. 49, 683s Year: 2005
Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008
Pilot: identification of rehospitalization risk factors for patients with COPD Source: Annual Congress 2005 - Assessment and intervention from primary care centre to hospital Year: 2005
Risk factors for moderate exacerbations in childhood asthma Source: Eur Respir J 2004; 24: Suppl. 48, 163s Year: 2004
Effect of omalizumab on the risk of hospitalisation in patients with uncontrolled severe asthma in real-life. The PAX-LASER cohort Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
Christmas as a risk factor for exacerbations of COPD, adult asthma and respiratory infections Source: Annual Congress 2007 - Environmental and clinical aspects of COPD Year: 2007
Specific comorbidities and low adherence are independent risk factors for poorer asthma control and exacerbations in patients with difficult-to-control asthma Source: International Congress 2019 – Long-term evaluation and control of airway diseases Year: 2019
Dupilumab efficacy in children with uncontrolled, moderate-to-severe asthma with and without an allergic phenotype Source: Virtual Congress 2021 – Advances in childhood asthma: biologics, biomarkers and infections Year: 2021